翰宇药业(300199) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥150,256,744.79, a decrease of 14.73% compared to ¥176,222,802.86 in the same period last year[23] - The net profit attributable to shareholders for Q1 2024 was -¥14,102,003.37, representing a decline of 175.79% from ¥18,605,574.69 in the previous year[23] - Total revenue for the first quarter was approximately ¥150.26 million, a decrease of 14.74% compared to ¥176.22 million in the previous period[36] - Operating profit turned negative at -¥4,914,615.80 compared to a profit of ¥20,189,134.88 in the previous year[54] - Total profit decreased to -¥9,599,404.04 from ¥16,922,305.70 year-over-year[54] - Net profit decreased to -¥14,350,051.02 from ¥18,265,336.47 year-over-year[54] - Basic and diluted earnings per share were both -¥0.02, compared to ¥0.02 in the same period last year[80] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥15,152,592.91, a 140.41% increase from -¥37,499,158.99 in Q1 2023[23] - Cash flow from operating activities decreased by 39.44% from ¥234,199,158.30 to ¥141,820,096.70[73] - Cash flow from financing activities increased by 521.95% from ¥50,770,057.91 to ¥315,765,898.81, primarily due to increased borrowings[73] - The net increase in cash and cash equivalents was -¥299,848,868.71, compared to -¥23,372,511.36 in the previous year, reflecting a significant decline of 1,182.91%[73] Assets and Liabilities - Total assets as of March 31, 2024, were ¥2,990,680,253.86, down 8.74% from ¥3,277,193,711.56 at the end of the previous year[23] - Current liabilities decreased from ¥1,423,438,972.66 to ¥1,028,243,878.09, a reduction of about 27.7%[78] - Total liabilities decreased from ¥2,493,982,435.70 to ¥2,216,432,117.41, a decrease of approximately 11.1%[78] - Non-current liabilities increased from ¥1,070,543,463.04 to ¥1,188,188,239.32, an increase of about 11%[78] - The company's total equity decreased from ¥783,211,275.86 to ¥774,248,136.45, a decline of approximately 1.22%[78] Expenses and Costs - Total operating costs for the first quarter were approximately ¥156.15 million, down from ¥201.09 million, reflecting a reduction of 22.34%[36] - Sales expenses for the first quarter were approximately ¥16.09 million, significantly reduced from ¥40.76 million, a decrease of 60.54%[36] - Management expenses decreased to approximately ¥29.82 million from ¥35.41 million, reflecting a reduction of 15.00%[36] - R&D expenses decreased by 57.20% to ¥18,999,351.04 from ¥44,393,211.43 year-over-year[54] - Other income decreased by 81.10% to ¥3,637,297.07 from ¥19,243,596.09 year-over-year[54] - Fair value changes in income dropped by 100.00% to ¥0 from ¥27,781,417.40 year-over-year[54] - Credit impairment losses increased by 91.78% to -¥3,388,149.62 from -¥1,766,646.00 year-over-year[54] Taxation - The company reported a significant increase in income tax expenses, which rose by 453.73% to ¥4,750,646.98 due to higher taxable income[7] - The company reported a tax expense of ¥4,750,646.98 compared to a tax benefit of -¥1,343,030.77 in the previous year[54] Other Notable Events - The company received government subsidies amounting to ¥3,430,488.73 during the reporting period[24] - The company has received approval for clinical trials of a new indication for Semaglutide injection (weight loss) from the National Medical Products Administration[11] - The company received a procurement order from a U.S. counterpart worth approximately $1.00 million (about ¥7.2 million), with total contracts signed over the past twelve months amounting to ¥175 million[32] - The company achieved a gross profit margin of approximately 62.43% in the first quarter, compared to 71.88% in the previous period[36] - The company received the FDA's "First Adequate Letter" for the production of liraglutide, indicating progress in the approval process for its GLP-1 liraglutide formulation[41] - The company's accounts receivable increased to approximately ¥170.92 million from ¥142.35 million, indicating a rise of 19.99%[34]